GLP-1 RA Use in Children With Obesity or Type 2 Diabetes
Abstract
Source: Kotecha P, Huang W, Yeh Y-Y, et al. Efficacy and safety of GLP-1 RAs in children and adolescents with obesity or type 2 diabetes: a systematic review and meta-analysis. JAMA Pediatr. 2025;179(12)1308-1317; doi: 10.1001/jamapediatrics.2025.3243.Investigators from multiple institutions conducted a systematic review and meta-analysis to assess the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of children and adolescents with obesity, prediabetes, or type 2 diabetes (T2D). For the study, they used a standardized process to identify randomized controlled trials (RCTs) comparing approved GLP-1 RAs to placebo in patients
Fields of Study & Subjects
Diabetes Treatment and Management
Diabetes Management and Research
Bariatric Surgery and Outcomes
Publication details
- Journal / source
- AAP Grand Rounds
- Volume
- 55
- Issue
- 1
- Pages
- 4–4
- Publication date
- 1 January 2026
- Language
- EN